The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update

[1]  Ludovico Minati,et al.  Test‐retest reliability of the default mode network in a multi‐centric fMRI study of healthy elderly: Effects of data‐driven physiological noise correction techniques , 2016, Human brain mapping.

[2]  P. Scheltens,et al.  Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease , 2015, Alzheimer's & Dementia.

[3]  Michael W. Weiner,et al.  Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 , 2015, Alzheimer's & Dementia.

[4]  Mark E. Schmidt,et al.  Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB) , 2015, Alzheimer's & Dementia.

[5]  Michael W. Weiner,et al.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2015, Alzheimer's & Dementia.

[6]  A. Simmons,et al.  Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer’s Disease in Two Independent Cohorts , 2014, Brain Topography.

[7]  N. Faux,et al.  An anemia of Alzheimer's disease , 2014, Molecular Psychiatry.

[8]  Magda Tsolaki,et al.  Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology , 2014, Alzheimer's & Dementia.

[9]  Magda Tsolaki,et al.  Plasma proteins predict conversion to dementia from prodromal disease , 2014, Alzheimer's & Dementia.

[10]  Magda Tsolaki,et al.  Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects , 2014, NeuroImage.

[11]  C. Rowe,et al.  Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment , 2014, Molecular Psychiatry.

[12]  P. Snyder,et al.  APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease , 2014, Molecular Psychiatry.

[13]  P. Mecocci,et al.  Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness , 2014, NeuroImage: Clinical.

[14]  A. Simmons,et al.  Predicting Progression of Alzheimer’s Disease Using Ordinal Regression , 2014, PloS one.

[15]  Magda Tsolaki,et al.  Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort , 2014, Front. Aging Neurosci..

[16]  Martha Brumfield,et al.  Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[17]  P. Rossini,et al.  CROSS-SECTIONAL BIOMARKER CHARACTERIZATION OF MILD COGNITIVE IMPAIRMENT PATIENTS IN WP5 PHARMACOG/E-ADNI STUDY , 2014, Alzheimer's & Dementia.

[18]  C. Jack,et al.  Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative , 2014, Alzheimer's & Dementia.

[19]  H. Kiiveri,et al.  A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study , 2014, Molecular Psychiatry.

[20]  K. Ishii,et al.  Visual-Statistical Interpretation of 18F-FDG-PET Images for Characteristic Alzheimer Patterns in a Multicenter Study: Inter-Rater Concordance and Relationship to Automated Quantitative Evaluation , 2014, American Journal of Neuroradiology.

[21]  Blaine R. Roberts,et al.  Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease , 2014, Alzheimer's & Dementia.

[22]  C. Rowe,et al.  Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.

[23]  Giovanni B. Frisoni,et al.  Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations , 2013, NeuroImage.

[24]  M. Weiner,et al.  Military risk factors for cognitive decline, dementia and Alzheimer's disease. , 2013, Current Alzheimer research.

[25]  Christos Davatzikos,et al.  Clinical and multimodal biomarker correlates of ADNI neuropathological findings , 2013, Acta Neuropathologica Communications.

[26]  Jason H. Moore,et al.  Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers , 2013, Brain Imaging and Behavior.

[27]  C. Rowe,et al.  Aβ amyloid, cognition, and APOE genotype in healthy older adults , 2013, Alzheimer's & Dementia.

[28]  J. Trojanowski,et al.  Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. , 2013, Brain : a journal of neurology.

[29]  Andrew P. Clark,et al.  Increased CNV-region deletions in mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects in the ADNI sample. , 2013, Genomics.

[30]  C. Rowe,et al.  Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing , 2013, Molecular Psychiatry.

[31]  C. Jack,et al.  Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging☆ , 2013, NeuroImage: Clinical.

[32]  M. Weiner,et al.  Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel , 2013, PloS one.

[33]  J. Trojanowski,et al.  CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease , 2013, Acta Neuropathologica.

[34]  Tetsuya Yuasa,et al.  Improved volumetric measurement of brain structure with a distortion correction procedure using an ADNI phantom. , 2013, Medical physics.

[35]  J. Trojanowski,et al.  Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. , 2013, Clinical chemistry.

[36]  S Lovestone,et al.  Classification and prediction of clinical diagnosis of Alzheimer's disease based on MRI and plasma measures of α‐/γ‐tocotrienols and γ‐tocopherol , 2013, Journal of internal medicine.

[37]  Tricia A. Thornton-Wells,et al.  Genetic interactions associated with 12-month atrophy in hippocampus and entorhinal cortex in Alzheimer's Disease Neuroimaging Initiative , 2013, Neurobiology of Aging.

[38]  Jason J. Corneveaux,et al.  Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment , 2013, Molecular Psychiatry.

[39]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[40]  Takashi Kato,et al.  Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: an analysis of 3D PET data from J-ADNI, a multi-center study , 2013, Annals of Nuclear Medicine.

[41]  M. Mintun,et al.  Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.

[42]  Anqi Qiu,et al.  CSF and Brain Structural Imaging Markers of the Alzheimer's Pathological Cascade , 2012, PloS one.

[43]  Jason J. Corneveaux,et al.  Analysis of Copy Number Variation in Alzheimer’s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals , 2012, PloS one.

[44]  Jerry L. Prince,et al.  A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.

[45]  S. O'Bryant.  Using blood markers for Alzheimer disease in clinical practice? , 2012, Neurology.

[46]  A. Simmons,et al.  Regional Magnetic Resonance Imaging Measures for Multivariate Analysis in Alzheimer’s Disease and Mild Cognitive Impairment , 2012, Brain Topography.

[47]  Eric Westman,et al.  Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion , 2012, NeuroImage.

[48]  L. Beckett,et al.  Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease , 2012, Brain Imaging and Behavior.

[49]  E. Erosheva,et al.  CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer’s pathological cascade , 2012, Brain Imaging and Behavior.

[50]  Marisa O. Hollinshead,et al.  Identification of common variants associated with human hippocampal and intracranial volumes , 2012, Nature Genetics.

[51]  Paul M. Thompson,et al.  Common variants at 12q14 and 12q24 are associated with hippocampal volume , 2012, Nature Genetics.

[52]  Michael W. Weiner,et al.  Genome-wide pathway analysis of memory impairment in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks , 2012, Brain Imaging and Behavior.

[53]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[54]  Yi Zhang,et al.  Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease , 2011, PloS one.

[55]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[56]  Magda Tsolaki,et al.  Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression. , 2011, Journal of Alzheimer's disease : JAD.

[57]  Alan E Hubbard,et al.  Longitudinal change of biomarkers in cognitive decline. , 2011, Archives of neurology.

[58]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[59]  A. Simmons,et al.  Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion , 2011, Alzheimer's & Dementia.

[60]  M. Weiner,et al.  Genomic Copy Number Analysis in Alzheimer's Disease and Mild Cognitive Impairment: An ADNI Study , 2011, International journal of Alzheimer's disease.

[61]  Kengo Ito,et al.  Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study , 2011, Annals of Nuclear Medicine.

[62]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[63]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[64]  C. Rowe,et al.  Plasma apolipoprotein E and Alzheimer disease risk , 2011, Neurology.

[65]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[66]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[67]  Danielle J. Harvey,et al.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes , 2010, Alzheimer's & Dementia.

[68]  Arthur W. Toga,et al.  The informatics core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[69]  Owen Carmichael,et al.  Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[70]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[71]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[72]  H. Soininen,et al.  Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer’s Disease , 2008, Neuroepidemiology.

[73]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[74]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[75]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[76]  P. Eikelenboom,et al.  The two faces of Alzheimer's disease , 2000, Journal of Neurology.

[77]  P. Scheltens,et al.  White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. , 1992, Brain : a journal of neurology.

[78]  J. Trojanowski,et al.  Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. , 2014, Journal of Alzheimer's disease : JAD.

[79]  Min Shi,et al.  α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. , 2013, Journal of Alzheimer's disease : JAD.

[80]  A. Simmons,et al.  Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[81]  Tricia A. Thornton-Wells,et al.  Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography , 2013, Human Genetics.

[82]  Anna Kinsey,et al.  Plasma transthyretin as a candidate marker for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[83]  S. Duchesne,et al.  Toward a dynamic biomarker model in Alzheimer's disease. , 2012, Journal of Alzheimer's Disease.

[84]  H. Soininen,et al.  Diagnostic accuracy of alzheimer’s disease: A neuropathological study , 2009, Acta Neuropathologica.

[85]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .